Specific genetic aberrations, such as RUNX1::RUNX1T1, CBFB::MYH11, and nucleophosmin 1 (NPM1) mutations, constitute markers of MRD but about 40% of children with AML harbor leukemia-specific targets, which makes these genetic targets clinically applicable in only minor fraction of children (6, 7). This evidence concerns the gene NPM1 and acute myeloid leukemia.